A Single-Arm, Phase 2 Study of Ramucirumab in Combination With Weekly Docetaxel in Patients With Stage IV Non-Small Cell Lung Cancer Following Disease Progression After Prior Platinum-Based Chemotherapy

Eli Lilly and Company0 sitesNovember 2016

ConditionsStage IV Non-small Cell Lung Cancer

InterventionsRamucirumab Docetaxel

DrugsRamucirumab Docetaxel

Overview

Phase: Phase 2
Intervention: Ramucirumab
Conditions: Stage IV Non-small Cell Lung Cancer
Sponsor: Eli Lilly and Company
Primary Endpoint: Percentage of Participants with Grade ≥3 Neutropenia
Status: Withdrawn
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

The main purpose of this study is to evaluate the safety of the study drug ramucirumab in combination with weekly docetaxel in participants with stage IV non-small cell lung cancer (NSCLC) following disease progression after prior platinum-based chemotherapy.

Registry

clinicaltrials.gov

Start Date

November 2016

End Date

January 2018

Last Updated

5 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Eli Lilly and Company

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•The participant had disease progression on or after prior platinum-based chemotherapy regimen for locally advanced or metastatic NSCLC.
•Prior immunotherapy for NSCLC is allowed.
•The participant has an Eastern Cooperative Oncology Group performance status of 0 or
•The participant has histologically or cytologically confirmed NSCLC.
•The participant has metastatic NSCLC disease (Stage IV) at the time of first dose of study treatment.
•The participant has measurable disease at the time of first dose of study treatment documented by computed tomography (CT) scan or magnetic resonance imaging (MRI).
•The participant has resolution to Grade ≤1 by the National Cancer Institute-common terminology criteria for adverse events (NCI-CTCAE), Version 4.0, of all clinically significant toxic effects of prior locoregional therapy, surgery, or other anticancer therapy.
•The participant has adequate organ function.
•The participant's urine protein is \<2+ on dipstick or routine urinalysis (UA). If urine dipstick or routine analysis indicates proteinuria ≥2+, then a 24-hour urine must be collected and must demonstrate \<2 grams of protein in 24 hours to allow participation in the study.
•For male participants, are sterile (including vasectomy confirmed by post vasectomy semen analysis) or agree to use a highly effective method of contraception (2 methods preferred, or per country requirements, whichever is more strict), and to not donate sperm starting with the first dose of study treatment, during the study, and for at least 6 months following the last dose of study treatment or country requirements, whichever is longer.

Exclusion Criteria

•Prior therapy with docetaxel or ramucirumab.
•The participant has received more than 1 prior chemotherapy regimen for locally advanced or metastatic NSCLC; however, prior maintenance chemotherapy for locally advanced or metastatic NSCLC is allowed.
•The participant's tumour contains small cell lung cancer.
•The participant has undergone major surgery within 28 days prior to first dose of study treatment, or subcutaneous venous access device placement within 7 days prior to first dose of study treatment. Furthermore, any participant with postoperative bleeding complications or wound complications from a surgical procedure performed in the last 2 months will be excluded.
•The participant has a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection (hemicolectomy or extensive small intestine resection with chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic diarrhea.
•The participant has peripheral neuropathy Grade ≥2 (NCI-CTCAE v 4.0).
•The participant has an elective or a planned major surgery during the course of the trial.
•The participant is receiving concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, chemoembolization, or targeted therapy.
•The participant has symptomatic, active, or untreated central nervous system (CNS) metastases. Brain metastases that are asymptomatic, stable and not requiring steroid use, and previously treated by radiation are allowed. The participant may have no evidence of Grade ≥1 CNS hemorrhage based on pretreatment MRI or I.V. contrast CT scan (performed within 21 days before first dose of study treatment).
•The participant has radiologically documented evidence of major blood vessel invasion or encasement by cancer.

Arms & Interventions

Ramucirumab + Docetaxel

Ramucirumab given intravenously (IV) on day 1 every 3 weeks followed by weekly IV infusion of docetaxel on days 1, 8, and 15 every 4 weeks.

Intervention: Ramucirumab

Ramucirumab + Docetaxel

Ramucirumab given intravenously (IV) on day 1 every 3 weeks followed by weekly IV infusion of docetaxel on days 1, 8, and 15 every 4 weeks.

Intervention: Docetaxel

Outcomes

Primary Outcomes

Percentage of Participants with Grade ≥3 Neutropenia

Time Frame: Baseline through End of Study (Approximately 20 Months)

Secondary Outcomes

Rate of Febrile Neutropenia(Baseline through End of Study (Approximately 20 Months))
Objective Response Rate (ORR): Percentage of Participants With a Complete or Partial Response(Baseline to Objective Progression or Start of New Anti-Cancer Therapy (Approximately 20 Months))
Progression Free Survival (PFS)(Baseline to Objective Progression or Death from Any Cause (Approximately 20 Months))
Overall Survival (OS)(Baseline to Date of Death Due to Any Cause (Approximately 20 Months))
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab(Baseline through End of Study (Approximately 20 Months))